Novartis AG (Novartis AG) Inventories, Finished Goods : $0 Mil (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Novartis AG Inventories, Finished Goods?

Novartis AG's quarterly finished goods increased from Sep. 2023 ($0 Mil) to Dec. 2023 ($1,448 Mil) but then declined from Dec. 2023 ($1,448 Mil) to Mar. 2024 ($0 Mil).

Novartis AG's annual finished goods declined from Dec. 2021 ($2,636 Mil) to Dec. 2022 ($2,568 Mil) and declined from Dec. 2022 ($2,568 Mil) to Dec. 2023 ($1,448 Mil).

Novartis AG Inventories, Finished Goods Historical Data

The historical data trend for Novartis AG's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Inventories, Finished Goods Chart

Novartis AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Finished Goods

Get a 7-Day Free Trial

2,207.00

2,840.00

2,636.00

2,568.00

1,448.00

Novartis AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Inventories, Finished Goods	Get a 7-Day Free Trial															-	-	-	1,448.00	-

Novartis AG Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Novartis AG (Novartis AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (OTCPK:NVSEF) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

NVS:USA NVS N:Mexico NOVNz:UK 0QLR:UK NOTA:Germany NOTA:Germany NOVNEE:Switzerland NOVN:Switzerland N1VS34:Brazil NVS:Argentina

Address

Lichtstrasse 35, Basel, CHE, 4056

Website

https://www.novartis.com

Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.